{"organizations": [], "uuid": "6d1c7e2e50d668ee37ee679135e73795998567f0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-incyte-merck-provide-update-on-pha/brief-incyte-merck-provide-update-on-phase-3-study-idUSASC09V4M", "country": "US", "domain_rank": 408, "title": "BRIEF-Incyte, Merck Provide Update On Phase 3 Study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-06T14:39:00.000+03:00", "replies_count": 0, "uuid": "6d1c7e2e50d668ee37ee679135e73795998567f0"}, "author": "", "url": "https://www.reuters.com/article/brief-incyte-merck-provide-update-on-pha/brief-incyte-merck-provide-update-on-phase-3-study-idUSASC09V4M", "ord_in_thread": 0, "title": "BRIEF-Incyte, Merck Provide Update On Phase 3 Study", "locations": [], "entities": {"persons": [{"name": "merck", "sentiment": "none"}], "locations": [], "organizations": [{"name": "merck provide update on phase", "sentiment": "negative"}, {"name": "merck", "sentiment": "negative"}, {"name": "incyte", "sentiment": "none"}, {"name": "incyte corp", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 6, 2018 / 11:40 AM / Updated 5 minutes ago BRIEF-Incyte, Merck Provide Update On Phase 3 Study Reuters Staff 1 Min Read \nApril 6 (Reuters) - Incyte Corp: \n* INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA \n* INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA \n* STUDY’S SECOND PRIMARY ENDPOINT OF OVERALL SURVIVAL ALSO IS NOT EXPECTED TO REACH STATISTICAL SIGNIFICANCE \n* BASED ON RESULTS, AND AT RECOMMENDATION OF EDMC, PHASE 3 STUDY WILL BE STOPPED \n* 252 WAS CONSISTENT WITH THAT OBSERVED IN STUDIES OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA \n* 252 STUDY EVALUATING EPACADOSTAT WITH KEYTRUDA DETERMINED STUDY DID NOT MEET PRIMARY ENDPOINT Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-06T14:39:00.000+03:00", "crawled": "2018-04-06T15:00:14.000+03:00", "highlightTitle": ""}